每经头条（nbdtoutiao）——实施城乡居民增收计划、降准降息等工具灵活高效运用、增加普通高中学 位……深度解读中央经济工作会议 （记者 曾健辉） 截至发稿，睿智医药市值为49亿元。 每经AI快讯，睿智医药（SZ 300149，收盘价：9.82元）12月12日晚间发布公告称，睿智医药科技股份 有限公司董事会秘书高莹莹女士因工作职务调整，申请辞去公司董事会秘书职务。 2025年1至6月份，睿智医药的营业收入构成为：医药研发服务及生产外包占比99.06%，益生元系列占 比0.52%，租金收入占比0.35%，其他行业占比0.07%。 ...

证券代码：300149 证券简称：睿智医药 公告编号：2025-80 睿智医药科技股份有限公司 关于高级管理人员辞职的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 电子邮箱：ir@chempartner.com 联系地址：广州市越秀区东风中路 268 号交易广场 28 楼 特此公告。 睿智医药科技股份有限公司（以下简称"公司"）董事会秘书高莹莹女士因工 作职务调整，申请辞去公司董事会秘书职务，辞职报告自送达董事会之日起生效。 高莹莹女士原定任期至公司第六届董事会届满为止。截至本公告披露日，高 莹莹女士未持有公司股份，亦不存在应当履行而未履行的承诺事项。 为保证董事会工作的正常进行，根据《公司法》《深圳证券交易所上市公司自 律监管指引第 2 号——创业板上市公司规范运作》《公司章程》等有关规定，公司 在聘任新的董事会秘书之前，公司董事会指定公司董事长、首席执行官（CEO） WOO SWEE LIAN 先生代行董事会秘书职责。公司将按照相关规定，尽快完成董 事会秘书的选聘工作。WOO SWEE LIAN 先生代行董事会秘书职责期间的联系方 式如下： 电话： ...

（文章来源：证券日报） 证券日报网讯 12月12日，睿智医药在互动平台回答投资者提问时表示，截至11月30日公司的股东人数 为39844户。 ...

炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 责任编辑：何俊熹 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 责任编辑：何俊熹 ...

在A股市场，上市公司董秘往往被视为连接公司与资本市场的"桥梁"，其任职者通常具备深厚的金融、 法律或行业专业背景。然而，睿智医药一则董秘聘任公告，却打破了市场对该岗位的固有认知——公司 拟聘任有多年广电主持经历的高莹莹担任新任董秘，此举迅速引发资本市场广泛关注。 投资者对这一人事任命褒贬不一。有观点认为高莹莹是外行，也有人认为其多年的媒体和主持人经验将 给公司品牌带来全新形象。 需要指出的是，睿智医药对董秘岗位的薪酬投入较为可观，该公司前任董秘2022~2024年三年间的平均 年薪约为154.08万元。如果延续这个薪酬水平，高莹莹未来的待遇也将较为丰厚。 从公开履历来看，高莹莹出生于1994年，本科学历，上海师范大学工商管理硕士在读。高莹莹自2016年 大学毕业就进入地方广播电视台，在随后的6年时间里先后任职于阳江广播电视台和中山广播电视台， 并担任策划、主持人、编导、编辑等职。其与双胞胎姐姐高晶晶共同主持过《晶莹睇透》《晶莹宝贝》 《文学悦听》《水上冲关》等栏目。期间，高莹莹还多次登上地方电视台春晚。 （文章来源：每日经济新闻） ...

Core Viewpoint - RuiZhi Pharmaceutical has appointed Gao Yingying as the new secretary of the board of directors following the resignation of Xu Jian due to work adjustments [1][5]. Group 1: Appointment Details - Gao Yingying's term as the board secretary will last until the end of the sixth board of directors [1]. - The appointment was approved by the board of directors after a nomination by Chairman Woo Sweelian [1]. Group 2: Background of Gao Yingying - Gao Yingying, born in 1994, has a bachelor's degree and is currently pursuing a master's degree in business administration at Shanghai Normal University [3]. - She has experience as a planner, host, and editor at various broadcasting stations from 2016 to 2022 [3][4]. - Prior to joining RuiZhi Pharmaceutical, she served as the promotion director at Zhongshan Anxin New Retail Co., Ltd. starting in November 2022 [4]. Group 3: Comparison with Previous Secretary - Xu Jian, the previous board secretary, was born in 1984 and held a master's degree in law from Sun Yat-sen University [4]. - Xu Jian had extensive experience in investment banking, having worked at Guohai Securities and Ping An Securities before joining RuiZhi Pharmaceutical in November 2021 [4][5]. Group 4: Company Performance - RuiZhi Pharmaceutical is a provider of integrated research and production services for biopharmaceuticals and chemical drugs [6]. - The company reported a total net loss exceeding 1.1 billion yuan over 2023 and 2024, with a revenue of 817 million yuan in the first three quarters of the current year, representing a year-on-year growth of 13.68% [6]. - The net profit attributable to shareholders for the same period was 7.09 million yuan, showing a significant increase of 111.5% year-on-year [6]. Group 5: Stock Performance - As of December 10, RuiZhi Pharmaceutical's stock price was 9.98 yuan per share, with a decline of 3.95% since the beginning of December [7]. - The company's latest market capitalization stands at 5 billion yuan [7].

Core Viewpoint - The appointment of Gao Yingying as the new secretary of the board for Ruizhi Pharmaceutical marks a significant leadership change within the company, highlighting a trend of cross-industry transitions in executive roles [2][6]. Group 1: Leadership Change - On December 1, Ruizhi Pharmaceutical announced the resignation of its previous board secretary, Xu Jian, due to work adjustments, and appointed Gao Yingying as the new board secretary [2]. - Gao Yingying, born in 1994, has a background in broadcasting and has held various roles in media before transitioning to the pharmaceutical industry [4][6]. - The company emphasized that Gao possesses the necessary experience and qualifications for the role, having completed training for board secretaries as required by regulations [6]. Group 2: Compensation - The annual pre-tax salary for the board secretary from 2022 to 2024 is reported to be 1.67 million yuan, 1.4443 million yuan, and 1.508 million yuan, averaging approximately 1.54 million yuan per year [7]. Group 3: Company Performance - Ruizhi Pharmaceutical has faced consecutive losses in 2023 and 2024, with a total net loss exceeding 1.1 billion yuan [9]. - In the first three quarters of the current year, the company achieved a revenue of 818 million yuan, representing a year-on-year growth of 13.68%, while the net profit attributable to shareholders was 7.09 million yuan, up 111.5% year-on-year [9]. Group 4: Market Position - As of December 10, the stock price of Ruizhi Pharmaceutical was reported at 9.98 yuan per share, with a decline of 3.95% since the beginning of December, and the company's latest market capitalization stands at 5 billion yuan [10].

每经记者｜黄宗彦 每经编辑｜段炼 吴永久 在A股市场，上市公司董秘往往被视为连接公司与资本市场的"桥梁"，其任职者通常具备深厚的金融、法律或行业专业背景。然而，睿智医药一则董秘聘 任公告，却打破了市场对该岗位的固有认知——公司拟聘任有多年广电主持经历的高莹莹担任新任董秘，此举迅速引发资本市场广泛关注。 投资者对这一人事任命褒贬不一。有观点认为高莹莹是外行，也有人认为其多年的媒体和主持人经验将给公司品牌带来全新形象。 需要指出的是，睿智医药对董秘岗位的薪酬投入较为可观，该公司前任董秘2022~2024年三年间的平均年薪约为154.08万元。如果延续这个薪酬水平，高 莹莹未来的待遇也将较为丰厚。 归根结底，外界所关注的核心问题是，抛开"美女主持人"的光环，这位无任何董秘和生物医药行业从业经历的新任董秘，将给公司带来哪些改变？ 春晚主持人担任董秘 外界褒贬不一 2025年12月1日，睿智医药发布《关于变更董事会秘书的公告》，宣布公司董事会审议通过议案，同意聘任高莹莹为公司新任董事会秘书，任期自本次董 事会审议通过之日起至公司第六届董事会届满之日止。公告同时披露，前任董秘许剑因工作调整原因申请辞职，其原定任期至202 ...

每经记者｜黄宗彦 每经编辑｜吴永久 在A股市场，上市公司董秘往往被视为连接公司与资本市场的"桥梁"，其任职者通常具备深厚的金融、法律或行业专业背景。然而，睿智医药一则董秘聘任 公告，却打破了市场对该岗位的固有认知——公司拟聘任有多年广电主持经历的高莹莹担任新任董秘，此举迅速引发资本市场广泛关注。 投资者对这一人事任命褒贬不一。有观点认为高莹莹是外行，也有人认为其多年的媒体和主持人经验将给公司品牌带来全新形象。 需要指出的是，睿智医药对董秘岗位的薪酬投入较为可观，该公司前任董秘2022~2024年三年间的平均年薪约为154.08万元。如果延续这个薪酬水平，高莹 莹未来的待遇也将较为丰厚。 归根结底，外界所关注的核心问题是，抛开"美女主持人"的光环，这位无任何董秘和生物医药行业从业经历的新任董秘，将给公司带来哪些改变？ 睿智医药聘春晚主持人担任董秘，外界褒贬不一 2025年12月1日，睿智医药发布《关于变更董事会秘书的公告》，宣布公司董事会审议通过议案，同意聘任高莹莹为公司新任董事会秘书，任期自本次董事 会审议通过之日起至公司第六届董事会届满之日止。公告同时披露，前任董秘许剑因工作调整原因申请辞职，其原定任期至2 ...

Market Performance - The medical services sector increased by 0.51% on December 8, with Chengdu XianDao leading the gains [1] - The Shanghai Composite Index closed at 3924.08, up 0.54%, while the Shenzhen Component Index closed at 13329.99, up 1.39% [1] Top Gainers in Medical Services - Chengdu XianDao (688222) closed at 23.20, up 1.75% with a trading volume of 45,700 shares and a turnover of 106 million yuan [1] - Other notable gainers include: - Guangzheng Eye Hospital (002524) at 4.63, up 1.54% [1] - MediXis (688202) at 53.96, up 1.35% [1] - WuXi AppTec (603259) at 91.55, up 1.27% with a significant turnover of 3.33 billion yuan [1] Top Losers in Medical Services - ST Zhongzhu (600568) closed at 2.79, down 2.11% with a trading volume of 614,600 shares and a turnover of 173 million yuan [2] - Other notable losers include: - Haoyuan Pharmaceutical (688131) at 74.35, down 1.50% [2] - Aoyang Health (002172) at 4.20, down 1.41% [2] Capital Flow Analysis - The medical services sector experienced a net outflow of 297 million yuan from institutional investors, while retail investors saw a net inflow of 317 million yuan [2][3] - Notable capital flows include: - WuXi AppTec (603259) with a net outflow of 30.81 million yuan from institutional investors [3] - NuoSiGe (301333) with a net inflow of 11.54 million yuan from institutional investors [3]